Current Opinion in Lipidology
- Metabolism of lipoprotein(a): new findings, implications and outstanding issues
- Regulation of lipoprotein lipase-mediated lipolysis of triglycerides
- The LDL cholesterol in stroke limbo: how low can we go?
- The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
- Apolipoprotein C-II: the re-emergence of a forgotten factor
- Remnant lipoproteins: are they equal to or more atherogenic than LDL?
- Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?
- Homozygous familial hypercholesterolemia: what treatments are on the horizon?
- Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?
- Editorial introduction
- Reducing residual cardiovascular risk with novel therapies
- Editorial: Clonal hematopoiesis: a link between inflammation, ageing and cardiovascular disease
- Editorial: Nitro-fatty acids: novel drug candidates for the co-treatment of atherosclerosis and nonalcoholic fatty liver disease
- Using the electronic health record for genomics research
- Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence
- Novel lecithin: cholesterol acyltransferase-based therapeutic approaches
- Tangier disease: update for 2020
- Inborn errors of apolipoprotein A-I metabolism: implications for disease, research and development
- Autosomal recessive hypercholesterolemia: update for 2020
- Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease